These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 24137610)

  • 1. Molecular mechanisms of hormone resistance of breast cancer.
    Scherbakov AM; Krasil'nikov MA; Kushlinskii NE
    Bull Exp Biol Med; 2013 Jul; 155(3):384-95. PubMed ID: 24137610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A role of SIPL1/SHARPIN in promoting resistance to hormone therapy in breast cancer.
    Ojo D; Wu Y; Bane A; Tang D
    Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):735-745. PubMed ID: 29248549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen receptor signaling as a target for novel breast cancer therapeutics.
    Renoir JM; Marsaud V; Lazennec G
    Biochem Pharmacol; 2013 Feb; 85(4):449-65. PubMed ID: 23103568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines.
    Sikora MJ; Jacobsen BM; Levine K; Chen J; Davidson NE; Lee AV; Alexander CM; Oesterreich S
    Breast Cancer Res; 2016 Sep; 18(1):92. PubMed ID: 27650553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The NFkappaB pathway and endocrine-resistant breast cancer.
    Zhou Y; Eppenberger-Castori S; Eppenberger U; Benz CC
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S37-46. PubMed ID: 16113098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The nuclear factor kappa B activation: the key step of cell proliferation in estrogen receptor-negative breast cancer cells].
    Wang HJ; Wu ZY; Fan P; Bian JM
    Zhonghua Wai Ke Za Zhi; 2005 Aug; 43(15):1014-6. PubMed ID: 16194364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
    Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
    IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression.
    Minoia M; Gentilin E; Molè D; Rossi M; Filieri C; Tagliati F; Baroni A; Ambrosio MR; degli Uberti E; Zatelli MC
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E907-16. PubMed ID: 22442272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Activation and prognostic significance of AKT, NF-kappaB and STAT3 in breast cancer with lymph node metastasis and estrogen receptor expression].
    Liu C; Zhou S; Ke CS; Li NP; Wu RL
    Ai Zheng; 2007 Sep; 26(9):929-36. PubMed ID: 17927847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consequences of the Convergence of Multiple Alternate Pathways on the Estrogen Receptor in the Treatment of Metastatic Breast Cancer.
    Glück S
    Clin Breast Cancer; 2017 Apr; 17(2):79-90. PubMed ID: 27687476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer.
    Cui X; Zhang P; Deng W; Oesterreich S; Lu Y; Mills GB; Lee AV
    Mol Endocrinol; 2003 Apr; 17(4):575-88. PubMed ID: 12554765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance.
    Sengupta S; Jordan VC
    Adv Exp Med Biol; 2008; 630():206-19. PubMed ID: 18637493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AR-PDEF pathway promotes tumour proliferation and upregulates MYC-mediated gene transcription by promoting MAD1 degradation in ER-negative breast cancer.
    Cao L; Xu C; Xiang G; Liu F; Liu X; Li C; Liu J; Meng Q; Jiao J; Niu Y
    Mol Cancer; 2018 Sep; 17(1):136. PubMed ID: 30217192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rhein inhibits angiogenesis and the viability of hormone-dependent and -independent cancer cells under normoxic or hypoxic conditions in vitro.
    Fernand VE; Losso JN; Truax RE; Villar EE; Bwambok DK; Fakayode SO; Lowry M; Warner IM
    Chem Biol Interact; 2011 Jul; 192(3):220-32. PubMed ID: 21457705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.
    Aesoy R; Sanchez BC; Norum JH; Lewensohn R; Viktorsson K; Linderholm B
    Mol Cancer Res; 2008 Oct; 6(10):1630-8. PubMed ID: 18922978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hormone resistance and its modulation in breast cancer].
    Kahán Z; Thurzó L
    Orv Hetil; 2005 Apr; 146(16):731-7. PubMed ID: 15889669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer.
    Rene Gonzalez R; Watters A; Xu Y; Singh UP; Mann DR; Rueda BR; Penichet ML
    Breast Cancer Res; 2009; 11(3):R36. PubMed ID: 19531256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationships between snail1 and estrogen receptor signaling in breast cancer cells.
    Scherbakov AM; Andreeva OE; Shatskaya VA; Krasil'nikov MA
    J Cell Biochem; 2012 Jun; 113(6):2147-55. PubMed ID: 22307688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The NF-KB pathway and endocrine therapy resistance in breast cancer.
    Khongthong P; Roseweir AK; Edwards J
    Endocr Relat Cancer; 2019 May; 26(6):R369-R380. PubMed ID: 32013374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.